ATC Group: L01DB01 Doxorubicin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01DB01 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01D Cytotoxic antibiotics and related substances
4 L01DB Anthracyclines and related substances
5 L01DB01 Doxorubicin

Active ingredients in L01DB01

Active Ingredient

Doxorubicin is a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects.

Related product monographs

Document Type Information Source  
 ADRIAMYCIN Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 CAELYX Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 CELDOXOME PEGYLATED LIPOSOMAL Concentrate for dispersion for infusion MPI, EU: SmPC European Medicines Agency (EU)
 ZOLSKETIL Concentrate for dispersion for infusion MPI, EU: SmPC European Medicines Agency (EU)

United States medicines

Medicines classified under this ATC code globally

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Germany (DE)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Nigeria (NG)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.